Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. <\/p>\n
Mannkind Corporation<\/strong> shares are trading higher as the company recently announced the U.S. Food and Drug Administration’s (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease. <\/p>\n MannKind (MNKD) Jumps On FDA Approval Of Furoscix ReadyFlow <\/p>\n The FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling caused by excess fluid trapped in the body’s tissue) in adults with heart failure or chronic kidney disease. <\/p>\n The product is notable for being the first autoinjector delivering IV-equivalent exposure, potentially allowing for quicker symptom relief and reducing the need for emergency interventions. <\/p>\n Don’t Miss:<\/strong> <\/p>\n Furoscix ReadyFlow provides a full 80 mg\/mL dose in a simple, patient-friendly format administered in under 10 seconds. <\/p>\n Heart failure affects approximately 6.7 million adults in the United States and is projected to increase to more than 8 million by 2030. <\/p>\n Concurrently, the biopharmaceutical company announced a private placement financing of approximately $50 million. <\/p>\n MannKind will use the proceeds for general corporate purposes, including funding the $45 million contingent value rights payment triggered by the recent FDA approval of Furoscix ReadyFlow. <\/p>\n MNKD Technical Analysis: Key Levels And Momentum <\/p>\n Mannkind’s stock is currently trading at $4.20, which is 2.5% above its 20-day simple moving average (SMA) of $4.11 and 11.7% above its 50-day SMA of $3.77. <\/p>\n Trending: <\/strong>Avoid the #1 Investing Mistake: How Your ‘Safe’ Holdings Could Be Costing You Big Time<\/strong><\/a> <\/p>\n The moving average convergence divergence (MACD) is below its signal line, indicating that momentum is fading, suggesting that the recent price increase may not be sustainable unless the stock can regain upward momentum. <\/p>\n MNKD Earnings Preview And Analyst Price Targets <\/p>\n The countdown is on: Mannkind Corporation is set to report earnings on August 5, 2026 (estimated). <\/p>\n How MannKind (MNKD) Ranks On Momentum And Value <\/p>\n Story Continues <\/p>\n Below is the Benzinga Edge scorecard for Mannkind, highlighting its strengths and weaknesses compared to the broader market: <\/p>\n Image via Shutterstock <\/p>\n Read Next:\u00a0<\/strong> <\/p>\n Building Wealth Across More Than Just the Market<\/strong> <\/p>\n Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That’s why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn’t tied to the fortunes of just one company or industry. <\/p>\n Arrived<\/strong> <\/p>\n Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100<\/strong><\/a>. This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly. <\/p>\n Realberry<\/strong> <\/p>\n Institutional-quality real estate has traditionally been difficult for individual investors to access. Realberry gives accredited investors direct access to private real estate opportunities <\/strong><\/a>backed by a team with 35 years of experience, $3.4 billion in assets under management, and $481 million in cumulative distributions paid to investors as of Q4 2025, according to the company. With a portfolio spanning 13 million square feet across seven U.S. states, Realberry focuses on acquiring, developing, and managing real estate with an emphasis on long-term value creation while its principals often invest alongside clients to help align interests. <\/p>\n FarmTogether<\/strong> <\/p>\n Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000<\/strong><\/a> \u2014 fully managed, with no landlord headaches. <\/p>\n Immersed<\/strong> <\/p>\n Immersed is building technology for the future of work through spatial computing.<\/strong><\/a> Known for its AR\/VR productivity platform that enables users to work across multiple virtual screens, the company has grown to more than 1.5 million users worldwide. Immersed is also developing Visor, a lightweight headset designed specifically for professional productivity, positioning the company at the intersection of remote work, extended reality (XR), and next-generation computing. <\/p>\n Fundrise<\/strong> <\/p>\n Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate<\/strong><\/a> <\/strong>and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth. <\/p>\n Mode Mobile<\/strong> <\/p>\n Mode Mobile is changing the way people interact with their phones by letting users earn money from the same apps and activities they already use every day.<\/strong><\/a> Instead of platforms keeping all the advertising revenue, Mode Mobile shares a portion back with users who engage with content, play games, and scroll on their devices. Named one of Deloitte’s fastest-growing software companies in North America, the company has built a large beta user base and is scaling a model that turns everyday smartphone usage into a potential income stream.\u00a0 <\/p>\n EquityMultiple<\/strong>\u00a0 <\/p>\n For accredited investors looking beyond stocks and bonds, <\/strong>EquityMultiple provides access to vetted commercial real estate deals starting at $5,000<\/strong><\/a>,<\/a> with only ~5% of opportunities passing their due diligence process. <\/p>\n \u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. <\/p>\n","protected":false},"excerpt":{"rendered":"Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Mannkind…\n","protected":false},"author":2,"featured_media":608510,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[79100,10933,18,6915,256998,135,138,19,17,99096,462],"class_list":["post-608509","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-biopharmaceutical-company","tag-chronic-kidney-disease","tag-eire","tag-food-and-drug-administration","tag-furoscix-readyflow","tag-health","tag-heart-failure","tag-ie","tag-ireland","tag-mannkind-corporation","tag-medication"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116998593869332019","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/608509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=608509"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/608509\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/608510"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=608509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=608509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=608509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}